News & Updates

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024 byStephen Padilla

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024
Hypo-, hyperthyroidism causally linked to pre-eclampsia
Hypo-, hyperthyroidism causally linked to pre-eclampsia
27 Nov 2024

Hyper- and hypothyroidism are causally associated with pre-eclampsia (PE), but PE does not causally influence thyroid dysfunctions, suggest the results of a Mendelian randomization (MR) study.

Hypo-, hyperthyroidism causally linked to pre-eclampsia
27 Nov 2024
ARBs a good alternative to ACEIs in patients with acute MI
ARBs a good alternative to ACEIs in patients with acute MI
20 Nov 2024

The incidence of death is comparable between patients with acute myocardial infarction (MI) without heart failure (HF) receiving angiotensin II receptor blockers (ARBs) and those taking angiotensin-converting enzyme inhibitors (ACEIs), a study has shown.

ARBs a good alternative to ACEIs in patients with acute MI
20 Nov 2024
Fruit, vegetable diet a viable treatment for hypertension
Fruit, vegetable diet a viable treatment for hypertension
19 Nov 2024